Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome

Z. Ryznarová, J. Keller, M. Záleský, R. Zachoval, V. Čapek, H. Malikova,

. 2019 ; 40 (1) : 41-50. [pub] -

Jazyk angličtina Země Švédsko

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022879

Grantová podpora
NV15-27047A MZ0 CEP - Centrální evidence projektů

PURPOSE: The main aim of the study was to compare the diagnostic performance of Prostate Imaging Reporting and Data System (PI-RADS) versions 1 and 2 for detection of prostate carcinoma (PCa) and clinically significant prostate carcinoma (CSPCa). The second aim was to evaluate the potential benefit of adding the apparent diffusion coefficient (ADC) and prostate specific antigen (PSA) density to the standard evaluation protocol. METHODS: A total of 167 consecutive patients with elevated PSA underwent magnetic resonance imaging. The images were evaluated prospectively using both versions of the PI-RADS and the results compared with 12-core template biopsy and magnetic resonance/transrectal ultrasound fusion biopsy. Receiver-operating characteristic (ROC) curves were compared for each scoring system using DeLong\'s test. The area under the curve (AUC) was calculated for ADC and PSA density for lesions scored 4. RESULTS: PI-RADS V2 had high discriminative ability for PCa prediction with an AUC of 0.824 (95% CI 0.763 to 0.885), compared to an AUC of 0.724 (95% CI 0.654 to 0.794) for PI-RADS V1 (p = 0.0335). ADC demonstrated a higher discriminative ability with an AUC of 0.702 (95% CI 0.548 to 0.856) in CSPCa prediction. Using the obtained ADC threshold of 828x10^-6 mm^2/s improved specificity to 86.73% with a sensitivity of 60.38%. CONCLUSION: PI-RADS version 2 exhibited significantly higher discriminative ability for PCa and CSPCa detection compared to PI-RADS version 1. Using the ADC can improve the tumor predictability of PI-RADS version 2 in lesions scored 4.

000      
00000naa a2200000 a 4500
001      
bmc20022879
003      
CZ-PrNML
005      
20201214124926.0
007      
ta
008      
201125s2019 sw f 000 0|eng||
009      
AR
035    __
$a (PubMed)31184822
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Ryznarová, Zuzana $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic.
245    10
$a Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome / $c Z. Ryznarová, J. Keller, M. Záleský, R. Zachoval, V. Čapek, H. Malikova,
520    9_
$a PURPOSE: The main aim of the study was to compare the diagnostic performance of Prostate Imaging Reporting and Data System (PI-RADS) versions 1 and 2 for detection of prostate carcinoma (PCa) and clinically significant prostate carcinoma (CSPCa). The second aim was to evaluate the potential benefit of adding the apparent diffusion coefficient (ADC) and prostate specific antigen (PSA) density to the standard evaluation protocol. METHODS: A total of 167 consecutive patients with elevated PSA underwent magnetic resonance imaging. The images were evaluated prospectively using both versions of the PI-RADS and the results compared with 12-core template biopsy and magnetic resonance/transrectal ultrasound fusion biopsy. Receiver-operating characteristic (ROC) curves were compared for each scoring system using DeLong\'s test. The area under the curve (AUC) was calculated for ADC and PSA density for lesions scored 4. RESULTS: PI-RADS V2 had high discriminative ability for PCa prediction with an AUC of 0.824 (95% CI 0.763 to 0.885), compared to an AUC of 0.724 (95% CI 0.654 to 0.794) for PI-RADS V1 (p = 0.0335). ADC demonstrated a higher discriminative ability with an AUC of 0.702 (95% CI 0.548 to 0.856) in CSPCa prediction. Using the obtained ADC threshold of 828x10^-6 mm^2/s improved specificity to 86.73% with a sensitivity of 60.38%. CONCLUSION: PI-RADS version 2 exhibited significantly higher discriminative ability for PCa and CSPCa detection compared to PI-RADS version 1. Using the ADC can improve the tumor predictability of PI-RADS version 2 in lesions scored 4.
650    _2
$a adenokarcinom $x diagnóza $x diagnostické zobrazování $x patologie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biopsie $7 D001706
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a prostata $x diagnostické zobrazování $x patologie $7 D011467
650    _2
$a nádory prostaty $x diagnóza $x diagnostické zobrazování $x patologie $7 D011471
650    _2
$a ultrasonografie $7 D014463
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Keller, Jiri $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Záleský, Miroslav $u Department of Urology, Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Zachoval, Roman $u Department of Urology, Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Čapek, Václav $u National Institute of Public Health, Prague, Czech Republic.
700    1_
$a Malikova, Hana $u Radiology Department, Third Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
773    0_
$w MED00168352 $t Neuro endocrinology letters $x 2354-4716 $g Roč. 40, č. 1 (2019), s. 41-50
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31184822 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124926 $b ABA008
999    __
$a ok $b bmc $g 1595198 $s 1113555
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 40 $c 1 $d 41-50 $e - $i 2354-4716 $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
GRA    __
$a NV15-27047A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...